The diagnostic utility of D2‐40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement

Differentiating malignant mesothelioma (MM) from pulmonary carcinoma in pleural fluid cytology can be challenging. Recent studies have suggested that D2‐40, a novel lymphatic marker, may be a useful marker for mesothelial differentiation in surgical specimens. However, there are no available data regarding its utility in effusion cytology specimens. We investigated the utility of D2‐40 in pleural fluid cytology in differentiating MM from pulmonary carcinomas. Twenty cases of pleural effusion smears of surgically confirmed MM with their corresponding cell blocks were retrieved from the database of the hospital computer system. We also included 10 cases of metastatic pulmonary adenocarcinoma (PA) and 10 cases metastatic pulmonary squamous cell carcinoma (PSCC) involving the pleural fluid. Cell blocks were formalin‐fixed, paraffin embedded, and immunostained for TTF1, p63, calretinin, CK5/6, WT‐1, and D2‐40. Cases were scored as negative (<5% positivity) or positive (>5% moderate/strong positivity). The positive rates for TTF1, p63, calretinin, CK5/6, WT‐1, and D2‐40 were as follows: MM (0/20), (0/20), (17/20), (18/20), (19/20), (17/20), for PA (8/10), (0/10), (3/10), (0/10), (0/10), (0/10), and for PSCC (1/10), (10/10), (6/10), (10/10), (0/15), (0/10). The staining pattern for D2‐40 was characterized by thick membranous staining. Diffuse cytoplasmic staining by D2‐40 was seen in 2 cases of pulmonary carcinoma, counted as negative. Our study showed that in differentiating MM from PA, CK5/6, WT‐1, and D2‐40 have high specificity and sensitivity for MM. Although calretinin is a sensitive IHC marker for MM, it is not specific since it stained 30% of PA. Conversely, to differentiate between MM and PSCC, p63 and WT‐1 are the best available markers. We recommend a panel of CK5/6, p63, D2‐40, and WT‐1 to differentiate MM from pulmonary carcinomas in effusion cytology specimens. Diagn. Cytopathol. 2006; 34:801–806. © 2006 Wiley‐Liss, Inc.

[1]  Dietel,et al.  Thyroid transcription factor‐1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B , 2000, Histopathology.

[2]  N. Ordóñez.  Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[3]  Alexander Marks,et al.  Monoclonal Antibody D2-40, a New Marker of Lymphatic Endothelium, Reacts with Kaposi's Sarcoma and a Subset of Angiosarcomas , 2002, Modern Pathology.

[4]  Leers,et al.  E‐cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma , 1998, Histopathology.

[5]  A. Hjerpe,et al.  An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma. , 2000, American journal of clinical pathology.

[6]  I. Downie,et al.  Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. , 2001, American journal of clinical pathology.

[7]  J. Oates,et al.  Anti‐cytokeratin 5/6: a positive marker for epithelioid mesothelioma , 1997, Histopathology.

[8]  U. Pastorino,et al.  p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? , 2002, The Journal of pathology.

[9]  N. Ordóñez.  Immunohistochemical diagnosis of epithelioid mesotheliomas: a critical review of old markers, new markers. , 2002, Human pathology.

[10]  A. Berner,et al.  The Role of Desmin and N-Cadherin in Effusion Cytology: A Comparative Study Using Established Markers of Mesothelial and Epithelial Cells , 2001, The American journal of surgical pathology.

[11]  N. Ordóñez.  Immunohistochemical diagnosis of epithelioid mesothelioma: an update. , 2009, Archives of pathology & laboratory medicine.

[12]  M. K. Kim,et al.  Immunohistochemical profile of common epithelial neoplasms arising in the kidney. , 2002 .

[13]  W. Grigioni,et al.  Immunohistochemical Panels For Differentiating Epithelial Malignant Mesothelioma From Lung Adenocarcinoma: A Study With Logistic Regression Analysis , 2001, The American journal of surgical pathology.

[14]  N. Ordóñez,et al.  Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. , 2000, The American journal of surgical pathology.

[15]  L. Ylagan,et al.  The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma , 2005, Diagnostic cytopathology.

[16]  N. Ordóñez,et al.  Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. , 1998, The American journal of surgical pathology.

[17]  G. Blobel,et al.  The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance. , 1985, The American journal of pathology.

[18]  F. Puglisi,et al.  TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung. , 1998, Cancer letters.

[19]  Alexander Marks,et al.  A New Monoclonal Antibody, D2-40, for Detection of Lymphatic Invasion in Primary Tumors , 2002, Laboratory Investigation.

[20]  D. Burstein,et al.  P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. , 2002, Human pathology.

[21]  D. Allred,et al.  Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas. , 2009, Archives of pathology & laboratory medicine.

[22]  G. Viale,et al.  Calretinin: a novel immunocytochemical marker for mesothelioma. , 1996, The American journal of surgical pathology.

[23]  Edwards,et al.  HBME‐1, MOC‐31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma , 2000, Histopathology.

[24]  I. Pastan,et al.  Monoclonal Antibody K1 Reacts With Epithelial Mesothelioma but not With Lung Adenocarcinoma , 1992, The American journal of surgical pathology.

[25]  A. D. Dei Tos,et al.  Calretinin: a novel tool for diagnostic immunohistochemistry. , 1998, Advances in Anatomic Pathology.

[26]  B. Schwaller,et al.  Alternative splicing of calretinin mRNA leads to different forms of calretinin. , 1995, European journal of biochemistry.

[27]  P. Chu,et al.  Expression of Cytokeratin 5/6 in Epithelial Neoplasms: An Immunohistochemical Study of 509 Cases , 2002, Modern Pathology.

[28]  N. Ordóñez.  D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. , 2005, Human pathology.

[29]  C. Kandaraki,et al.  Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids , 2005, Diagnostic cytopathology.

[30]  H. Cramer,et al.  Cytologic diagnosis of malignant mesothelioma, with particular emphasis on the epithelial noncohesive cell type , 1999, Diagnostic cytopathology.

[31]  J. Morris,et al.  Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. , 1995, The American journal of pathology.

[32]  N. Ordóñez.  The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study , 2006, Modern Pathology.

[33]  L. Litzky,et al.  Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma , 2005, Modern Pathology.

[34]  N. Ordóñez.  In search of a positive immunohistochemical marker for mesothelioma: an update. , 1998, Advances in anatomic pathology.

[35]  H. Yeger,et al.  Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours , 1999, British Journal of Cancer.

[36]  B. Addis,et al.  Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies , 2002, Journal of clinical pathology.